Does the Addition of Cetuximab to Radiochemotherapy Improve Outcome of Patients with Locally Advanced Rectal Cancer? Long-Term Results from Phase II Trials
Table 1
Characteristics of patients with locally advanced rectal cancer receiving capecitabine/irinotecan +/− cetuximab based chemoradiotherapy as preoperative treatment.
Capecitabine/irinotecan ()
Capecitabine/irinotecan + cetuximab ()
value
Gender, (%)
Male
29 (78)
33 (67)
Female
8 (22)
16 (33)
Fisher’s exact test
0.33
Age (years); median (range)
60 (34–82)
57 (33–80)
Unpaired -test
0.79
Clinical TNM stage, (%)
cT1
0 (0)
0 (0)
cT2
4 (11)
9 (18)
cT3
28 (76)
36 (73)
cT4
4 (11)
4 (8)
cTx
1 (3)
0 (0)
Chi square
0.62
cN−
6 (16)
15 (31)
cN+
31 (84)
34 (69)
Fisher’s exact test
0.14
Tumor distance from anal verge (cm); median (range)